FourThought Financial LLC Acquires 33 Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX)

FourThought Financial LLC increased its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX – Get Rating) by 10.3% in the third quarter, HoldingsChannel reports. The firm owned 354 shares of the company’s stock after purchasing an additional 33 shares during the period. FourThought Financial LLC’s holdings in IDEXX Laboratories were worth $115,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. Ronald Blue Trust Inc. bought a new stake in IDEXX Laboratories in the second quarter worth $34,000. Carolinas Wealth Consulting LLC bought a new stake in IDEXX Laboratories during the first quarter valued at about $39,000. Riverview Trust Co boosted its holdings in IDEXX Laboratories by 202.8% during the third quarter. Riverview Trust Co now owns 109 shares of the company’s stock valued at $36,000 after acquiring an additional 73 shares during the period. Atlas Capital Advisors LLC bought a new stake in IDEXX Laboratories during the second quarter valued at about $44,000. Finally, Advanced Research Investment Solutions LLC bought a new stake in IDEXX Laboratories during the third quarter valued at about $52,000. 87.90% of the stock is currently owned by institutional investors.

IDEXX Laboratories Stock Down 0.6 %

Shares of IDXX opened at $471.36 on Friday. The company has a 50-day simple moving average of $481.48 and a 200-day simple moving average of $414.74. The firm has a market capitalization of $39.08 billion, a P/E ratio of 58.70, a P/E/G ratio of 2.74 and a beta of 1.18. The company has a debt-to-equity ratio of 1.14, a quick ratio of 0.59 and a current ratio of 0.89. IDEXX Laboratories, Inc. has a 52 week low of $317.06 and a 52 week high of $560.92.

IDEXX Laboratories (NASDAQ:IDXX – Get Rating) last posted its quarterly earnings results on Monday, February 6th. The company reported $2.05 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.92 by $0.13. IDEXX Laboratories had a net margin of 20.17% and a return on equity of 124.51%. The firm had revenue of $828.60 million during the quarter, compared to analyst estimates of $820.91 million. During the same quarter in the prior year, the business posted $1.89 earnings per share. The company’s quarterly revenue was up 3.4% compared to the same quarter last year. On average, equities research analysts expect that IDEXX Laboratories, Inc. will post 9.58 earnings per share for the current year.

Wall Street Analyst Weigh In

IDXX has been the subject of a number of recent analyst reports. StockNews.com initiated coverage on shares of IDEXX Laboratories in a report on Thursday. They set a “buy” rating for the company. TheStreet upgraded shares of IDEXX Laboratories from a “c+” rating to a “b-” rating in a report on Friday, November 25th. The Goldman Sachs Group upped their price target on shares of IDEXX Laboratories from $465.00 to $530.00 and gave the company a “buy” rating in a report on Wednesday, January 25th. Barclays upped their price target on shares of IDEXX Laboratories from $582.00 to $590.00 and gave the company an “overweight” rating in a report on Wednesday, February 8th. Finally, Atlantic Securities upped their price objective on shares of IDEXX Laboratories from $470.00 to $600.00 and gave the company an “overweight” rating in a research report on Tuesday, February 7th. Two equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $514.75.

Insider Buying and Selling

In related news, SVP Kathy V. Turner sold 2,000 shares of the stock in a transaction dated Tuesday, February 14th. The shares were sold at an average price of $504.59, for a total value of $1,009,180.00. Following the completion of the transaction, the senior vice president now owns 7,380 shares of the company’s stock, valued at $3,723,874.20. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In other IDEXX Laboratories news, SVP Kathy V. Turner sold 1,000 shares of the company’s stock in a transaction dated Thursday, February 9th. The shares were sold at an average price of $505.04, for a total transaction of $505,040.00. Following the sale, the senior vice president now directly owns 6,941 shares of the company’s stock, valued at $3,505,482.64. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, SVP Kathy V. Turner sold 2,000 shares of the company’s stock in a transaction dated Tuesday, February 14th. The stock was sold at an average price of $504.59, for a total transaction of $1,009,180.00. Following the sale, the senior vice president now directly owns 7,380 shares in the company, valued at $3,723,874.20. The disclosure for this sale can be found here. Company insiders own 2.06% of the company’s stock.

About IDEXX Laboratories

(Get Rating)

IDEXX Laboratories, Inc engages in the development, manufacture, and distribution of products and services for the animal veterinary, livestock and poultry, dairy, and water testing markets. It operates through the following segments: Companion Animal Group (CAG), Water Quality Products (Water), Livestock, Poultry, and Dairy (LPD), and Other.